ATE354364T1 - Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind - Google Patents

Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind

Info

Publication number
ATE354364T1
ATE354364T1 AT99964665T AT99964665T ATE354364T1 AT E354364 T1 ATE354364 T1 AT E354364T1 AT 99964665 T AT99964665 T AT 99964665T AT 99964665 T AT99964665 T AT 99964665T AT E354364 T1 ATE354364 T1 AT E354364T1
Authority
AT
Austria
Prior art keywords
receptors
increase
treatment
receptor
diseases associated
Prior art date
Application number
AT99964665T
Other languages
English (en)
Inventor
Gillian Rosemary Bullock
Gasparo Marc De
Sabina Maria Ganter
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE354364(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP98811258A external-priority patent/EP1013273A1/de
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE354364T1 publication Critical patent/ATE354364T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99964665T 1998-12-23 1999-12-22 Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind ATE354364T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98811258A EP1013273A1 (de) 1998-12-23 1998-12-23 Verwendung von AT-1 Rezeptorantagonisten oder AT-2 Rezeptormodulatoren zur Behandlung von Erkrankungen, die mit einer Erhöhung an AT-1 oder AT-2 Rezeptoren verbunden sind
EP98811257 1998-12-23

Publications (1)

Publication Number Publication Date
ATE354364T1 true ATE354364T1 (de) 2007-03-15

Family

ID=26152118

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05013209T ATE524176T1 (de) 1998-12-23 1999-12-22 Valsartan tablette
AT99964665T ATE354364T1 (de) 1998-12-23 1999-12-22 Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05013209T ATE524176T1 (de) 1998-12-23 1999-12-22 Valsartan tablette

Country Status (26)

Country Link
EP (3) EP1140071B1 (de)
JP (2) JP2002533390A (de)
KR (1) KR100646716B1 (de)
CN (2) CN1636561A (de)
AT (2) ATE524176T1 (de)
AU (4) AU3043000A (de)
BR (1) BR9916576A (de)
CA (2) CA2351357A1 (de)
CY (2) CY1106581T1 (de)
CZ (2) CZ293257B6 (de)
DE (1) DE69935249T2 (de)
DK (2) DK1140071T3 (de)
ES (2) ES2373556T3 (de)
HK (1) HK1038888B (de)
HU (1) HUP0104780A3 (de)
ID (1) ID29856A (de)
IL (5) IL143233A0 (de)
NO (2) NO328775B1 (de)
NZ (3) NZ511938A (de)
PL (1) PL199100B1 (de)
PT (2) PT1140071E (de)
RU (3) RU2271809C2 (de)
SI (2) SI1140071T1 (de)
SK (1) SK9132001A3 (de)
TR (7) TR200805740T1 (de)
WO (1) WO2000038676A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK18062002A3 (sk) * 2000-06-22 2003-07-01 Novartis Ag Pevné orálne farmaceutické kompozície obsahujúce valsartan
JP4972847B2 (ja) * 2000-10-11 2012-07-11 住友化学株式会社 コラーゲン蓄積抑制剤
JPWO2002083127A1 (ja) * 2001-04-09 2004-09-30 宮田　敏男 蛋白修飾物生成抑制組成物
AU2002257970B2 (en) 2001-05-31 2007-08-02 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
CA2466659A1 (en) * 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticancer agents
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2005041941A2 (en) * 2003-11-03 2005-05-12 Zentiva, A.S. Valsartan containing formulation
AU2005318365B2 (en) 2004-12-24 2011-02-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
CN102861019B (zh) * 2004-12-24 2016-05-25 诺华股份有限公司 治疗或预防神经性疼痛的药物
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2139473A1 (de) * 2007-03-29 2010-01-06 Alembic Limited Valsartan-tablettenformulierungen
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
EP2197416A1 (de) 2007-10-09 2010-06-23 Novartis Ag Pharmazeutische formulierung von valsartan
PL2295035T3 (pl) 2007-11-06 2016-11-30 Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep)
US20110104166A1 (en) * 2008-01-18 2011-05-05 Stankovic Konstantina M Methods and Compositions for Treating Polyps
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
WO2010104485A2 (en) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
EP2455388A1 (de) 2010-11-23 2012-05-23 LanthioPep B.V. Neuartige Rezeptoragonisten von Angiotensin des Typs 2 (AT2) und Verwendungen dafür
CN102266307B (zh) * 2011-08-01 2012-10-24 海南锦瑞制药股份有限公司 一种缬沙坦胶囊及其制备方法
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
US20220257698A1 (en) 2019-08-02 2022-08-18 Lanthiopep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
EP4295839A1 (de) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Kombination aus valsartan und indapamid
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146168A (en) * 1962-04-10 1964-08-25 Fmc Corp Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0330284B1 (de) * 1988-02-25 1994-07-27 Yamanouchi Europe B.V. Verfahren zur Herstellung eines pharmazeutischen Granulats
DE69033469T2 (de) 1989-06-14 2000-09-07 Smithkline Beecham Corp., Philadelphia Imidazoalkensäure
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
TW201738B (de) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
WO1992005784A1 (en) * 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
US5591762A (en) * 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4132632A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
DE4309968A1 (de) * 1993-03-26 1994-09-29 Bayer Ag Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten
ES2135472T3 (es) 1992-04-13 1999-11-01 Zeneca Ltd Antagonistas de angiotensina ii contra trastornos asociados con la velocidad de conduccion neuronal deteriorada, especialmente la neuropatia diabetica.
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
KR950704259A (ko) * 1992-12-11 1995-11-17 베르너 발데크 치환된 벤즈아제피논(Substituted Benzazepinone)
AU685768B2 (en) 1992-12-11 1998-01-29 Novartis Ag Benzazepinone derivatives
DE4309963A1 (de) * 1993-03-26 1994-09-29 Hubert Kamperschroer Faß zum Austragen von Gülle
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
BR9507086A (pt) * 1994-03-17 1997-09-16 Ciba Geigy Ag Tratamento de nefroterapia diabética com valsartan
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
DE69624253T2 (de) 1995-10-06 2003-08-07 Novartis Ag, Basel Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
WO1997031624A1 (en) 1996-02-27 1997-09-04 Purdue Research Foundation Liposomal delivery system
DE69718146T2 (de) * 1996-02-29 2003-10-02 Novartis Ag, Basel At1 rezeptor antagonist zur anregung von apoptosis
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
EP1146872B1 (de) * 1999-01-26 2006-06-21 Novartis AG Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
SK18062002A3 (sk) * 2000-06-22 2003-07-01 Novartis Ag Pevné orálne farmaceutické kompozície obsahujúce valsartan
US20070123498A1 (en) 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
JP2009018990A (ja) 2005-10-25 2009-01-29 Univ Kurume Ｃ型肝炎ウイルス由来ペプチド

Also Published As

Publication number Publication date
AU2009220022B2 (en) 2011-11-03
NO20100041L (no) 2001-08-16
TR200805275T2 (tr) 2008-09-22
RU2361575C2 (ru) 2009-07-20
IL143233A (en) 2007-07-24
EP1588706B1 (de) 2011-09-14
JP2002533390A (ja) 2002-10-08
IL179015A0 (en) 2007-03-08
CA2622805C (en) 2011-05-10
NO20013143D0 (no) 2001-06-22
CY1106581T1 (el) 2012-01-25
NZ511938A (en) 2004-02-27
NZ587909A (en) 2012-05-25
AU2003266433A1 (en) 2004-01-08
HUP0104780A2 (hu) 2002-04-29
HK1038888B (en) 2007-09-21
ATE524176T1 (de) 2011-09-15
EP2298298A3 (de) 2011-05-11
DK1140071T3 (da) 2007-06-04
SI1588706T1 (sl) 2012-01-31
NZ553010A (en) 2008-09-26
AU2006203077B2 (en) 2009-10-08
CZ297795B6 (cs) 2007-03-28
CN1304000C (zh) 2007-03-14
IL143233A0 (en) 2002-04-21
PT1588706E (pt) 2011-12-21
PL199100B1 (pl) 2008-08-29
ID29856A (id) 2001-10-18
KR20010089681A (ko) 2001-10-08
CZ20012306A3 (cs) 2001-12-12
EP1588706A3 (de) 2005-12-07
ES2281978T3 (es) 2007-10-01
RU2005124363A (ru) 2007-02-10
HK1038888A1 (en) 2002-04-04
TR200101784T2 (tr) 2001-10-22
JP2010090169A (ja) 2010-04-22
RU2008143545A (ru) 2010-05-10
IL179016A0 (en) 2007-03-08
DE69935249D1 (de) 2007-04-05
TR200605472T1 (tr) 2007-02-21
DE69935249T2 (de) 2007-10-31
AU2006203077A1 (en) 2006-08-10
SI1140071T1 (sl) 2007-08-31
TR200200764T2 (tr) 2002-07-22
CA2351357A1 (en) 2000-07-06
BR9916576A (pt) 2001-10-02
TR200805740T1 (tr) 2010-06-21
AU2003266433B2 (en) 2006-08-10
TR200805741T2 (tr) 2008-10-21
WO2000038676A1 (en) 2000-07-06
AU2009220022A1 (en) 2009-10-15
EP1140071A1 (de) 2001-10-10
JP5254258B2 (ja) 2013-08-07
CA2622805A1 (en) 2000-07-06
IL179017A0 (en) 2007-03-08
EP1140071B1 (de) 2007-02-21
EP2298298A2 (de) 2011-03-23
DK1588706T3 (da) 2012-01-16
TR200605471T2 (tr) 2006-11-21
KR100646716B1 (ko) 2006-11-17
NO328775B1 (no) 2010-05-10
ES2373556T3 (es) 2012-02-06
PT1140071E (pt) 2007-05-31
CY1112395T1 (el) 2015-12-09
PL349424A1 (en) 2002-07-29
EP1588706A2 (de) 2005-10-26
RU2271809C2 (ru) 2006-03-20
CN1636561A (zh) 2005-07-13
CN1331590A (zh) 2002-01-16
AU3043000A (en) 2000-07-31
HUP0104780A3 (en) 2002-11-28
CZ293257B6 (cs) 2004-03-17
NO20013143L (no) 2001-08-16
SK9132001A3 (en) 2002-01-07

Similar Documents

Publication Publication Date Title
DE69935249D1 (de) Verwendung von at-1 rezeptorantagonisten oder at-2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
IL146871A0 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
EA199700116A1 (ru) Трициклические бензазепины как антагонисты вазопрессина, способ их получения, фармкомпозиция на их основе и способ лечения
FI943542A0 (fi) Trisyklisiä bentsatsepiineja, jotka ovat vasopressiiniantagonisteja
IS5113A (is) Notkun antagónista CB1-viðtaka til meðhöndlunar löngunartruflana
PT94181A (pt) Processo para a preparacao de heterociclos com 6 membros imidazo-condensados substituidos uteis como antagonistas de angiotensina ii
WO1999026927A3 (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases
MY131442A (en) Excitatory amino acid receptor antagonists
EP1679313A3 (de) Heteropolycyclische Verbindungen und ihre Verwendung als Antagonisten des metabotropischen Glutamat-Rezeptors
DE69033308D1 (de) Decahydro-isochinolin-derivate
PL331617A1 (en) Treatment of allergic response on the part of upper airways by means of a combination od histamine receptor antagonists
ATE439861T1 (de) Verfahren zur modulierung von cd200-rezeptoren
DE68912459D1 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE446748T1 (de) Verwendung von r-carprofen zur vorbeugung der alzheimerschen krankheit
ATE330599T1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
DE69530600D1 (de) Verwendung von nk1-rezeptor antagonisten zur zubereitung von arzneimitteln mit kardioregulierender wirkung
IT8959368V0 (it) Immobilizzatore complesso dell'arto superiore a politrazione regolabile.
WO2002007726A3 (en) Treatment of movement disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140071

Country of ref document: EP

RZN Patent revoked